Streetbeat News

Regulatory

ELAN

ZTS

Elanco Animal Health's new dermatology treatment, Zenrelia, received FDA approval for treating itchy dogs. Despite its efficacy, concerns about label warnings and adverse events may affect its market adoption. Elanco's stock fell 4.18% following the news.

Portfolio Pulse from Vandana Singh

September 20, 2024 | 2:35 pm

ICUI

Smiths Medical has recalled its Parapac Plus ventilators due to a loosened patient outlet connector, which has resulted in one injury and one death. The FDA has classified this as the most serious type of recall.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 2:33 pm

HKXCF

Hong Kong will implement a new rule on Sept. 23 to keep its stock market open during severe weather events, aligning with global practices. Analysts believe this will have limited impact on trading volumes, suggesting that measures like reducing trading taxes could be more effective in attracting investors.

Portfolio Pulse from The Bamboo Works

September 20, 2024 | 1:54 pm

AAPL

MSFT

NVDA

SpotGamma founder Brent Kochuba discusses potential market turbulence due to the Federal Reserve's interest rate decision and expiring derivatives. He highlights the impact of options trading on market volatility, particularly concerning large-cap stocks like Nvidia, Apple, and Microsoft. Kochuba warns of continued volatility risks and emphasizes the importance of monitoring options flows.

Portfolio Pulse from Renato Capelj

September 20, 2024 | 1:48 pm

ADA-USD

ETH-USD

Charles Hoskinson, co-founder of Ethereum and Cardano, expressed concerns about a new DeFi platform backed by Donald Trump, fearing it could politicize the crypto industry and lead to regulatory challenges. He highlighted the risks of political involvement in crypto and the potential for investigations by U.S. institutions.

Portfolio Pulse from Khyathi Dalal

September 20, 2024 | 1:20 pm

APLS

Apellis Pharmaceuticals' shares are declining following the European Medicines Agency's Committee for Medicinal Products for Human Use reaffirming its negative opinion on the company's drug, intravitreal pepcetacoplan, for treating geographic atrophy secondary to age-related macular degeneration.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 1:17 pm

SNY

Sanofi's phase 3 study of tolebrutinib shows promising results in delaying disability progression in multiple sclerosis patients, despite some adverse events. The study supports future regulatory discussions, with submissions planned for H2 2024.

Portfolio Pulse from Vandana Singh

September 20, 2024 | 1:16 pm

CVS

LLY

WBA

Eli Lilly is appealing a $183 million judgment for allegedly defrauding Medicaid by underreporting drug prices. The case has drawn attention from major business groups due to its potential impact on regulated companies. Eli Lilly claims it adhered to Medicaid rules.

Portfolio Pulse from Vandana Singh

September 20, 2024 | 1:11 pm

NVDA

NVO

TSLA

The European Drug Agency has backed Novo Nordisk's Wegovy for obesity-related heart failure, while Bitcoin's correction ends with a target to reach $70K. Nvidia and Tesla rally as the Dow and S&P 500 hit new highs after Fed rate cuts.

Portfolio Pulse from Akanksha Bakshi

September 20, 2024 | 1:04 pm

QLGN

Qualigen Therapeutics has been granted an extension by Nasdaq to meet compliance requirements for continued listing until November 19, 2024.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 1:02 pm